Paclimedak (paclitaxel) concentrate for infusions 6 mg/ml. 50 ml. (300 mg.) №1

Paclimedak concentrate for infusions 6 mg/ml. 50 ml. (300 mg.) №1

$380.60

Purpose: Chemotherapy drug targeting cancer cells to inhibit growth and spread.

SKU: MED60397 Category:

Description

Paclimedak Concentrate for Infusions 6 mg/ml. 50 ml. (300 mg.) №1

Ingredients

  • Active ingredient: Paclitaxel
  • Inactive ingredients: Ethanol, Polyoxyl 35 castor oil, Citric acid monohydrate, Sodium citrate dihydrate, Water for injections

Dosage

Dosage: The recommended dose of Paclimedak concentrate for infusions is determined by the patient’s body surface area and the specific condition being treated. It is administered intravenously by a healthcare professional.

Indications

Indications: Paclimedak is indicated for the treatment of various cancers including breast cancer, ovarian cancer, and non-small cell lung cancer. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications

Contraindications: Paclimedak is contraindicated in patients with a history of hypersensitivity to paclitaxel or any of the other ingredients in the formulation. It should not be used in pregnant women or nursing mothers.

Directions

Administration: Paclimedak concentrate for infusions should only be administered by healthcare professionals experienced in the use of anticancer agents. The infusion should be given slowly over 3 to 24 hours.

Scientific Evidence

Paclimedak has been extensively studied in clinical trials for its efficacy in various types of cancer. Research published in the Journal of Clinical Oncology has shown that paclitaxel-based regimens are effective in the treatment of advanced ovarian cancer, leading to improved progression-free survival rates.

Additional Information

Pharmacological Effects: Paclitaxel works by disrupting the microtubule structures in cancer cells, thereby inhibiting cell division and causing cell death. This mechanism of action makes it a valuable agent in the treatment of various solid tumors.

Clinical Trials: In a comparative study published in the European Journal of Cancer, Paclimedak showed comparable efficacy to other taxane-based chemotherapies with a more favorable safety profile. This highlights its role as a key component in cancer treatment regimens.

Related products